(19)
(11) EP 3 515 456 A1

(12)

(43) Date of publication:
31.07.2019 Bulletin 2019/31

(21) Application number: 17853747.8

(22) Date of filing: 19.09.2017
(51) International Patent Classification (IPC): 
A61K 31/7088(2006.01)
C12N 15/113(2010.01)
 A61P 35/00(2006.01)
(86) International application number:
PCT/US2017/052246
(87) International publication number:
WO 2018/057506 (29.03.2018 Gazette 2018/13)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 20.09.2016 US 201662397062 P

(71) Applicant: Medimmune, LLC
Gaithersburg, Maryland 20878 (US)

(72) Inventors:
  • HIGGS, Brandon, W.
    Gaithersburg MD 20878 (US)
  • MOREHOUSE, Chris
    Gaithersburg MD 20878 (US)
  • BROHAWN, Philip
    Gaithersburg MD 20878 (US)
  • STREICHER, Katie
    Gaithersburg MD 20878 (US)
  • RANADE, Koustubh
    Gaithersburg MD 20878 (US)

(74) Representative: AstraZeneca 
Milstein Building Granta Park
Cambridge CB21 6GH
Cambridge CB21 6GH (GB)

   


(54) COMPOSITIONS AND METHODS FOR CHARACTERIZING SOLID TUMORS RESPONSIVENESS TO ANTI-PD-L1 ANTIBODY MONOTHERAPY